News

Aslan has gained rights to develop and market BMS-777607 in Australia,China, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains rights at the rest of the

After filing IND (Investigational New Drug) with the FDA and the completion of the phase IIb study, the Company licensed the global rights of Lupuzor to Cephalon. Following

Lixisenatide, discovered by Zealand Pharma and licensed to Sanofi, is a once-daily GLP-1 receptor agonist for Type-2 diabetes . Sanofi is set to complete Phase III development of

The double-blind, multicentre, placebo-controlled, randomised CUV030 study was designed to assess the safety and efficacy of subcutaneous bioresorbable afamelanotide implants in reducing phototoxic skin reactions in erythropoietic protoporphyria

Mibefradil, used for cancer treatment, is a T-type calcium channel blocker which arrests tumor cells at their most vulnerable metabolic point. TAU Therapeutics is developing Mibefradil. Scynexis and

The research will be run by the company’s AbD Serotec unit for three additional years. As per the deal, Shionogi will continue to have the right to use

The funds are received by a facility which tests new cancer drugs, a project dealing with lung cancer treatment undertaken by a biopharmaceutical company on a new drug

B-Chillin comprises therapeutic dosages of eight stress-reducing nutrients, including magnesium, chloride, L-theanine, GABA, seawater trace mineral concentrate, lemon balm, holy basil, and chamomile. Amrion founder and chairman of

Apokyn (apomorphine hydrochloride injection) is used to treat acute hypomobility ‘off’ episodes linked to advanced Parkinson’s disease. Following the move, Ipsen will not record Apokyn sales in its